Myeloid-derived suppressor cells promote tumor growth and sorafenib resistance by inducing FGF1 upregulation and fibrosis

BACKGROUND: Considerable evidence implicates myeloid-derived suppressor cells (MDSCs) promote tumor progression and drug resistance. Sorafenib is the standard first-line therapy for advanced hepatocellular carcinoma (HCC). Clinical evidence indicates that sorafenib resistance is associated with incr...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Xue, Li, Xueyan, Guo, Xuan, Lu, Yantong, Xie, Yingjie, Huang, Xuhui, Lin, Juze, Tan, Wei, Wang, Changjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2022
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980488/
https://www.ncbi.nlm.nih.gov/pubmed/35378464
http://dx.doi.org/10.1016/j.neo.2022.100788

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980488/
https://www.ncbi.nlm.nih.gov/pubmed/35378464
http://dx.doi.org/10.1016/j.neo.2022.100788

Ejemplares similares